Navigation Links
CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
Date:4/15/2011

ming CryoLife successfully acquires 49.9 percent of Cardiogenesis' outstanding shares in the tender offer, CryoLife expects that the shares acquired in the tender offer together with shares held by the officers and directors of Cardiogenesis that are subject to a support agreement that requires them to be voted in favor of the merger will be sufficient to assure approval of the merger.

A more detailed description of the Cardiogenesis Board of Directors' recommendation can be found in the Solicitation/Recommendation Statement on Schedule 14D-9 prepared by Cardiogenesis, which has been mailed to Cardiogenesis shareholders and which was filed with the SEC, as amended.  Additionally, CryoLife and CL Falcon, Inc. have filed with the SEC a tender offer statement on Schedule TO, as amended, including an Offer to Purchase, Letter of Transmittal and other related materials setting forth in detail the terms of the tender offer.  Copies of the Offer to Purchase, Letter of Transmittal and other related materials, including the Solicitation/Recommendation Statement, are available from Georgeson Inc., the information agent for the tender offer at 800-676-0098 (Toll Free).  Banks and brokers are asked to call 212-440-9800.  Computershare Inc. is acting as depositary for the tender offer.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly per
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S.
2. David P. Lang Appointed Vice President of CryoLife International, Inc.
3. CryoLife to Present at UBS Global Life Sciences Conference
4. CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
5. CryoLife to Present at UBS Global Life Sciences Conference
6. CryoLife Announces First Clinical Use of BioFoam(R)
7. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
8. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
9. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
10. CryoLife Reports Record First Quarter Revenues of $26.7 Million
11. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
(Date:3/4/2015)... 2015 Proove Biosciences , ... is excited to announce the launch of their ... the Management of Pain”. , The continuing medical ... the next year. The focus of the program ... inadequate pain treatments, integrate appropriate pain management techniques, ...
(Date:3/4/2015)... San Jose, California (PRWEB) March 04, 2015 ... Chain Reaction (PCR) represents one of the fastest growing ... among cell biologists in subcellular visualization is driving growth ... The need for deeper understanding of gene expressions will ... reagents market. Expanding applications in fields ranging from pharma, ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... Wash., March 11 SCOLR Pharma, Inc. (NYSE Alternext ... and twelve months ended December 31, 2008. The ... 11, 2009, at 11:30 a.m. (Eastern Daylight Time)."Last year ... and CEO Bruce S. Morra, Ph.D., M.B.A. "Utilizing our ...
... Serve Future Requirements of Stem Cell ResearchersST. LOUIS, March ... announced the launch of an online web portal that ... of industry-leading products developed specifically for advanced stem cell ... highly-focused products that are expected to support every step ...
... March 11 Insmed Inc. (Nasdaq: INSM ), a developer of ... ended December 31, 2008. Company Highlights , ... Insmed entered into ... will purchase all assets related to Insmed,s follow-on biologics platform. , ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 7SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 8Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal 2Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal 3Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 10
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... the Johns Hopkins School of Medicine and their colleagues have ... addition to their own can acquire new color vision, a ... new sensory information than anticipated. , This work, appearing ... ancestral primate inherited a new type of photoreceptor more than ...
... aren't as busy as, well, a bee. It all ... that a key to the insects' success in adapting to ... temperatures when flying to flowers. Whether and how they ... from the University of Washington and the University of Puget ...
... Schulich School of Medicine & Dentistry at The University ... Edinburgh, have discovered a way to kill the cystic ... of Dr. Miguel Valvano, Department of Microbiology and Immunology, ... of the Journal of Bacteriology, and highlighted in Nature ...
Cached Biology News:Making mice with enhanced color vision 2Making mice with enhanced color vision 3Bumblebee house warming -- it takes a village 2Bumblebee house warming -- it takes a village 3Key found to kill cystic fibrosis superbug 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: